Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 5/20 | 0.63 |
| ▸ | F2 | P00734 | 4/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.58 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.56 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.55 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30233460 | 0.97 | CALCR (0.59) | CALCRF2HCRTR1HCRTR2OPRM1 | |
| SCHEMBL30753755 | 0.95 | CALCR (0.62) | CALCRF2HCRTR1HCRTR2OPRM1 | |
| SCHEMBL30788353 | 0.95 | CALCR (0.60) | CALCRF2HCRTR1HCRTR2OPRM1 | |
| SCHEMBL30233337 | 0.94 | CALCR (0.60) | CALCRF2HCRTR1HCRTR2OPRM1 | |
| SCHEMBL30233281 | 0.94 | C5AR1 (0.63) | CALCRF2HCRTR1HCRTR2C5AR1 | |
| SCHEMBL30788341 | 0.94 | CALCR (0.58) | CALCRF2HCRTR1HCRTR2OPRM1 | |
| SCHEMBL30233222 | 0.93 | CALCR (0.62) | CALCRF2HCRTR1HCRTR2OPRM1 | |
| SCHEMBL30233449 | 0.93 | CALCR (0.58) | CALCRF2OPRM1OPRD1C5AR1 | |
| SCHEMBL30753761 | 0.93 | OPRD1 (0.61) | CALCROPRM1OPRD1 | |
| SCHEMBL30233254 | 0.93 | OPRD1 (0.61) | CALCROPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240041740-A1 | SKIN PEEL COMPOSITIONS | GLO PHARMA INC (US) | 2024-02-08 | — | — | US | disclosed |
| CN-115702161-A | Peptide compositions and methods for inhibiting nicotinic acetylcholine receptor activity | 格罗制药公司 | 2023-02-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | CALCR 128/4885F2 2151/4885HCRTR1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.